Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07207811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Study acronym: CLEOPATTRA
StatusRecruiting
PhasePhase 3
Started2025-10-02
View on ClinicalTrials.gov ↗
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

Amendment history 3 changes detected by DataLookout

2026-08-20
Trial sites expanded: 292 → 295 locations
2026-04-28
Primary endpoint(s) modified
WasNumber of occurrences of composite endpoint of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits)
NowComposite Outcome of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits)
2026-04-28
Trial sites expanded: 285 → 289 locations
Trial Details
NCT Number NCT07207811
Lead Sponsor Novo Nordisk A/S
Conditions Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Enrollment 1,280 participants
Start Date 2025-10-02
Primary Completion 2029-06-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-19